Skip to main content

OB/GYN Clinical Alert

RSS  

Articles

  • Special Feature: Intrauterine Growth Restriction

    Recently, there has been an increased focus on the identification of fetal anomalies and aneuploidy through first and early second trimester maternal testing, which has improved early identification of these disorders.
  • Testing for Chlamydia and Gonorrhea in Pregnancy

    The authors performed a retrospective cohort study of 1,293,423 pregnant women aged 16 to 40 in the United States from June 1, 2005 to May 30, 2008, using data from the Quest Diagnostics Informatics Data Warehouse.
  • Sentinel-Node Biopsy in Endometrial Cancer: Valid Approach?

    Previous studies have demonstrated the feasibility of identifying sentinel lymph nodes (SLN) in the pelvic and para-aortic nodal basins in women with endometrial cancer.
  • What the Internet Says about Pelvic Organ Prolapse and Urinary Incontinence

    These authors from Louisiana State University and the University of Hawaii set out to evaluate the quality of information available on the Internet regarding pelvic organ prolapse and urinary incontinence.
  • Pharmacology Watch: Does Aspirin Prevent Cancer?

    In this issue: Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
  • Estrogen and Breast Cancer

    Subjects in the Women's Health Initiative (WHI) trial estrogen-only study randomized to receive conjugated estrogens had a lower incidence of invasive breast cancer than did those who received placebo.
  • Clinical Briefs in Primary Care supplement

  • Special Feature: Fetal DNA Testing for Aneuploidy Detection

    Currently, screening for fetal aneuploidy involves a variety of first-line methods that put into play combinations of maternal serum analytes and ultrasound exams in the first and second trimester, with invasive procedures such as chorionic villus sampling (CVS) and amniocentesis being reserved for those at higher risk by history, age, or worrisome results from first-line screening. As will be discussed, each screening combination comes with its own predictive accuracy and now patients and providers can choose from a buffet of screening options, including going right to the main course (amniocentesis or CVS) if one wants 100% accuracy at a small risk of fetal loss (we quote a 1 in 400 risk with amniocentesis and about a 1 in 100 risk for CVS).
  • Paracervical Block for Pain Control

    The authors performed a randomized, single-blind trial of the effects of a paracervical block (PCB) or sham block on pain with cervical dilation and aspiration during first trimester abortion. Enrollment of subjects was stratified by gestational age (early: < 8 weeks, n = 60; late: 8-10 6/7 weeks, n = 60).
  • Shoulder Dystocia

    For years, clinicians have been trying to find ways to predict shoulder dystocia (SD), a complication that can have serious consequences for some infants and, on occasion, for the providers who delivered these babies.